Literature DB >> 1818332

Effects of antimitotic agents on tubulin-nucleotide interactions.

J J Correia1.   

Abstract

The interaction of antimitotic drugs with guanine nucleotides in the tubulin-microtubule system is reviewed. Antimitotic agent-tubulin interactions can be covalent, entropic, allosteric or coupled to other equilibria (such as divalent cation binding, alternate polymer formation, or the stabilization of native tubulin structure). Antimitotics bind to tubulin at a few common sites and alter the ability of tubulin to form microtubules. Colchicine and podophyllotoxin compete for a common overlapping binding site but only colchicine induces GTPase activity and large conformational changes in the tubulin heterodimer. The vinca alkaloids, vinblastine and vincristine, the macrocyclic ansa macrolides, maytansine and ansamitocin P-3, and the fungal antimitotic, rhizoxin, share and compete for a different binding site near the exchangeable nucleotide binding site. The macrocyclic heptapeptide, phomopsin A, and the depsipeptide, dolastatin 10, bind to a site adjacent to the vinca alkaloid and nucleotide sites. Colchicine, vinca alkaloids, dolastatin 10 and phomopsin A induce alternate polymer formation (sheets for colchicine, spirals for vinblastine and vincristine and rings for dolastatin 10 and phomopsin A). Maytansine, ansamitocin P-3 and rhizoxin inhibit vinblastine-induced spiral formation. Taxol stoichiometrically induces microtubule formation and, in the presence of GTP, assembly-associated GTP hydrolysis. Analogs of guanine nucleotides also alter polymer morphology. Thus, sites on tubulin for drugs and nucleotides communicate allosterically with the interfaces that form longitudinal and lateral contacts within a microtubule. Microtubule associated proteins (MAPs), divalent cations, and buffer components can alter the surface interactions of tubulin and thus modulate the interactions between antimitotic drugs and guanine nucleotides.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1818332     DOI: 10.1016/0163-7258(91)90004-6

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  10 in total

Review 1.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

2.  Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.

Authors:  Manu Lopus; Emin Oroudjev; Leslie Wilson; Sharon Wilhelm; Wayne Widdison; Ravi Chari; Mary Ann Jordan
Journal:  Mol Cancer Ther       Date:  2010-10       Impact factor: 6.261

3.  Divalent cation and ionic strength effects on Vinca alkaloid-induced tubulin self-association.

Authors:  S Lobert; C A Boyd; J J Correia
Journal:  Biophys J       Date:  1997-01       Impact factor: 4.033

4.  Investigation of anti-tumor mechanisms of K2154: characterization of tubulin isotypes, mitotic arrest and apoptotic machinery.

Authors:  Pin-Hsuan Lu; Fan-Lu Kung; Sheng-Chu Kuo; Shih-Chieh Chueh; Jih-Hwa Guh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-11       Impact factor: 3.000

5.  Different effects of vinblastine on the polymerization of isotypically purified tubulins from bovine brain.

Authors:  Israr A Khan; Richard F Ludueña
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

6.  Mutations of oncoprotein 18/stathmin identify tubulin-directed regulatory activities distinct from tubulin association.

Authors:  N Larsson; B Segerman; H M Gradin; E Wandzioch; L Cassimeris; M Gullberg
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

7.  Tryprostatin A, a specific and novel inhibitor of microtubule assembly.

Authors:  T Usui; M Kondoh; C B Cui; T Mayumi; H Osada
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

8.  Molecular, Biological and Structural Features of VL CDR-1 Rb44 Peptide, Which Targets the Microtubule Network in Melanoma Cells.

Authors:  Natalia Girola; Pedro T Resende-Lara; Carlos R Figueiredo; Mariana H Massaoka; Ricardo A Azevedo; Rodrigo L O R Cunha; Luciano Polonelli; Luiz R Travassos
Journal:  Front Oncol       Date:  2019-01-25       Impact factor: 6.244

9.  Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review.

Authors:  Marie Lindhard Madsen; Hanne Due; Niels Ejskjær; Paw Jensen; Jakob Madsen; Karen Dybkær
Journal:  Cancer Chemother Pharmacol       Date:  2019-06-18       Impact factor: 3.333

10.  Neutropenia in dogs receiving vincristine for treatment of presumptive immune-mediated thrombocytopenia.

Authors:  Kathryn A LaQuaglia; James B Robertson; Katharine F Lunn
Journal:  J Vet Intern Med       Date:  2021-01-09       Impact factor: 3.175

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.